Valuation : Arrowhead Pharmaceuticals, Inc.

Market Cap 11.7B 10.08B 9.55B 8.65B 16.24B 1,118B 16.32B 113B 43.61B 569B 43.95B 42.99B 1,797B P/E 2026 *
-22.8x
P/E 2027 * -18x
Enterprise Value 10.87B 9.37B 8.87B 8.04B 15.08B 1,039B 15.16B 105B 40.5B 528B 40.83B 39.93B 1,670B EV / Sales 2026 *
23.6x
EV / Sales 2027 * 32.4x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -
1 day+0.11%
1 week-4.04%
Current month+0.56%
1 month-5.04%
3 months+11.18%
6 months+50.61%
Current year+24.79%
1 week 80.33
Extreme 80.33
87.2
1 month 80.33
Extreme 80.33
90.21
Current year 54.02
Extreme 54.02
95.49
1 year 28.12
Extreme 28.12
95.49
3 years 9.57
Extreme 9.57
95.49
5 years 9.57
Extreme 9.57
95.49
10 years 1.2
Extreme 1.2
95.49
Manager TitleAgeSince
Chief Executive Officer 56 2007-11-30
Director of Finance/CFO - 2025-05-12
Chief Tech/Sci/R&D Officer - 2022-07-31
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 2010-08-18
Director/Board Member 66 2011-12-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 Sell

Director

-2,000 0.0014%
8/18/26 Sell

Director

-11,600 0.0082%
6/15/26 Free

Director

11,882 0.0084%
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%-4.04%+178.77%+184.71% 11.7B
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.26%-3.06%+45.46%+241.19% 28.21B
Weighted average by Cap. -0.53%-2.88%+37.37%+171.24%

Financials

2026 *2027 *
Net sales 461M 397M 376M 341M 640M 44.06B 643M 4.47B 1.72B 22.42B 1.73B 1.69B 70.83B 340M 293M 277M 251M 472M 32.48B 474M 3.29B 1.27B 16.52B 1.28B 1.25B 52.21B
Net income -518M -447M -423M -383M -719M -49.53B -723M -5.02B -1.93B -25.2B -1.95B -1.9B -79.63B -650M -560M -530M -480M -901M -62.05B -906M -6.29B -2.42B -31.57B -2.44B -2.39B -99.76B
Net Debt -832M -717M -679M -615M -1.15B -79.52B -1.16B -8.07B -3.1B -40.46B -3.13B -3.06B -128B -683M -588M -557M -505M -947M -65.23B -952M -6.62B -2.54B -33.19B -2.56B -2.51B -105B
Logo Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
711
Date Price Change Volume
26-09-11 US$82.85 +0.11% 1,335,818
26-09-10 US$82.76 +0.16% 1,020,398
26-09-09 US$82.63 -2.91% 3,668,389
26-09-08 US$85.11 -1.42% 1,568,097
26-09-04 US$86.34 -0.17% 757,847
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
82.85USD
Average target price
110.00USD
Spread / Average Target
+32.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARWR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!